scholarly journals Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
K. Ina Ly ◽  
Bella Vakulenko-Lagun ◽  
Kyrre E. Emblem ◽  
Yangming Ou ◽  
Xiao Da ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Functional Mri ◽  
Newly Diagnosed ◽  
Adjuvant Temozolomide ◽  
Newly Diagnosed Glioblastoma

scholarly journals Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
K. Ina Ly ◽  
Bella Vakulenko-Lagun ◽  
Kyrre E. Emblem ◽  
Yangming Ou ◽  
Xiao Da ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Functional Mri ◽  
Newly Diagnosed ◽  
Adjuvant Temozolomide ◽  
Newly Diagnosed Glioblastoma

scholarly journals A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma

2010 ◽  
Vol 12 (10) ◽  
pp. 1071-1077 ◽  
Author(s):  
M. R. Rosenfeld ◽  
M. C. Chamberlain ◽  
S. A. Grossman ◽  
D. M. Peereboom ◽  
G. J. Lesser ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Study ◽  
Newly Diagnosed ◽  
Adjuvant Temozolomide ◽  
Newly Diagnosed Glioblastoma

scholarly journals Reply to: “Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?”

2020 ◽  
Vol 22 (12) ◽  
pp. 1889-1890
Author(s):  
Carmen Balana ◽  
Cristina Carrato ◽  
Maria Angeles Vaz
Keyword(s):  
Newly Diagnosed ◽  
Adjuvant Temozolomide ◽  
Newly Diagnosed Glioblastoma

scholarly journals Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

2017 ◽  
Vol 19 (8) ◽  
pp. 1119-1126 ◽  
Author(s):  
Deborah T. Blumenthal ◽  
Thierry Gorlia ◽  
Mark R. Gilbert ◽  
Michelle M. Kim ◽  
L. Burt Nabors ◽  
...  
Keyword(s):  
Secondary Analysis ◽  
Newly Diagnosed ◽  
Adjuvant Temozolomide ◽  
Newly Diagnosed Glioblastoma ◽  
The Impact

EORTC Study 26041–22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma—Results of a phase I trial

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 2026-2026 ◽  
Author(s):  
A. A. Brandes ◽  
R. Stupp ◽  
P. Hau ◽  
S. Sleijfer ◽  
D. Lacombe ◽  
...  
Keyword(s):  
Phase I ◽  
Kinase Inhibitor ◽  
Standard Dose ◽  
Dose Finding ◽  
Hepatic Toxicity ◽  
Newly Diagnosed ◽  
Triple Combination ◽  
Adjuvant Temozolomide ◽  
Newly Diagnosed Glioblastoma ◽  
Fixed Standard

2026 Background: VEGF is an essential mediator of angiogenesis. PTK/ZK is an orally available tyrosine kinase inhibitor of all known VEGF receptors. The EORTC has initiated a randomized phase I/II study in which PTK/ZK is being investigated in combination with standard RT and concomitant TMZ. The results of the safety and dose-finding run-in of the triple combination are reported here. Methods: Escalating doses of PTK/ZK QD continuously (using classical 3+3 design) and concomitant RT (60 Gy) and TMZ (75 mg/m2/day) during 6–7 weeks were to be administered. During the adjuvant/maintenance part, PTK/ZK was prescribed at a fixed standard dose of 750mg bid until progression. Dose limiting toxicities (DLT) were defined as >G3 toxicity occurring during RT + 2 weeks. Results: 18 GBM pts (M/F: 11/7, median age: 53 years, PS 0/1) have been enrolled and complete data for 15 pts are currently available. DL1 (500 mg): 4 pts; no DLT; DL2 (1000 mg): 6 pts: 1 DLT: G3, liver enzyme (ALAT) elevation and hyponatremia DL3 (1250 mg); 8 pts: 3 DLTs: G3 hepatic toxicity (2 pts) and G3 platelets and G4 neutrophil (1 pt). In a 4th patient a G3 diarrhea and hepatic DLT leading to PTK/ZK interruption was doubtful therefore it was decided to extend DL3. Frequently observed possibly related non-dose limiting drug adverse events of all grades included: abdominal pain/cramping (2 pts), ALAT/ASAT elevation (10 pts), creatinine elevation (2 pts), allergic reaction (2 pts), constipation (4 pts), diarrhea (5 pts), fatigue (11 pts), hypertension (6 pts), nausea (8 pts), vomiting (3 pts), and weight loss (4 pts). All toxicities were reversible. Conclusions: MTD has been reached at 1250 mg and the recommended dose of PTK/ZK in combination with RT and TMZ is 1000 mg/day. A randomized 3-arm phase II will start accrual in January 2007. Patients will receive standard TMZ/RT alone or with PTK/ZK starting at the beginning of radiotherapy or at the beginning of adjuvant therapy 4 weeks after the end of radiotherapy. [Table: see text]

scholarly journals ATPS-74IS MORE CHEMOTHERAPY BETTER? PROLONGED SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA RECEIVING MORE THAN SIX CYCLES OF ADJUVANT TEMOZOLOMIDE

2015 ◽  
Vol 17 (suppl 5) ◽  
pp. v34.4-v34 ◽  
Author(s):  
Jacob Ruzevick ◽  
Emily Silgard ◽  
Carrie Graham ◽  
Maciej Mrugala
Keyword(s):  
Prolonged Survival ◽  
Newly Diagnosed ◽  
Adjuvant Temozolomide ◽  
Newly Diagnosed Glioblastoma

scholarly journals Expression and prognostic value of CD80 and CD86 in the tumor microenvironment of newly diagnosed glioblastoma

2022 ◽  
pp. 1-22
Author(s):  
Mohammed H Ahmed ◽  
Isaias Hernández-Verdin ◽  
Franck Bielle ◽  
Maite Verreault ◽  
Julie Lerond ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Prognostic Value ◽  
Newly Diagnosed ◽  
Newly Diagnosed Glioblastoma
Sign in / Sign up

Export Citation Format

Share Document